Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment

Inclusion Criteria:

• Patients aged ≥ 40 years.

• Osteoarthritis of the hand according to American College of Rheumatology criteria 1990

• Osteoarthritis affecting at least two proximal and/or distal interphalangeal jointswith a radiological Kellgren-Lawrence stage ≥ 2.

• Symptomatic osteoarthritis within the last 3 months.

• Visual analogue pain scale of the hand to be treated ≥ 40/100 mm (most painfulhand).

• Inadequate response, adverse effects and/or contraindication to NSAIDs andnon-opioid analgesics.

• Patient affiliated to french social security or a similar health assurance.

Exclusion Criteria:

• History of allergy to iodinated contrast media, LipiodolⓇ or poppies.

• Vasomotor disorders (Raynaud's syndrome, scleroderma, acrocyanosis).

• Stenosis (>50%) or known atheromatous arterial occlusion of the upper limbs.

• Obliterative arterial disease of the lower limbs at the critical ischaemia stage.

• Severe to end-stage chronic renal insufficiency (glomerular filtration rate < 30ml/min/1.73m2), dialysis or renal transplant.

• Arteritis such as thromboangiitis obliterans disease or other diseases

• Previous thrombosis/dissection of the radial artery.

• Chronic inflammatory rheumatic disease (rheumatoid arthritis, psoriatic arthritis,microcrystalline arthritis, etc.).

• Known hyperthyroidism or large multinodular goiter.

• Traumatic lesions, haemorrhages or chronic bleeding in the hand (not completelyresolved within 3 months of the start of the lesion) requiring embolisation.

• Pregnant or breast-feeding.

• Patients covered by articles L1121-5 to L1121-8 of the French Public Health Codeand/or who do not speak French.

• Patients in a period of exclusion or in the course of another interventionalclinical trial.